Literature DB >> 15378433

Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents.

Anna-Barbara Moscicki1, Jonas H Ellenberg, Peggy Crowley-Nowick, Teresa M Darragh, Jiahong Xu, Sepidah Fahrat.   

Abstract

BACKGROUND: The risk of developing the human papillomavirus (HPV)-associated precancer high-grade squamous intraepithelial lesion (HSIL) in human immunodeficiency virus (HIV)-infected adolescents is unknown. We examined the risk of developing HSIL among adolescents with and without HIV infection.
METHODS: HIV-infected (n = 172) and -uninfected (n = 84) girls aged 13-18 years who were participating in a multicenter study of primarily horizontally acquired HIV infections in adolescents (Reaching for Excellence in Adolescent Health Care) and who did not have HSIL on cytologic examination at study entry or at the first follow-up visit were followed at 6-month intervals. HIV-uninfected girls were recruited for comparison in a 2:1 ratio (HIV infected:HIV uninfected). The primary outcome was cytologic diagnosis of HSIL confirmed by expert review.
RESULTS: Incidence of HSIL by the end of follow-up was higher for HIV-infected girls than for HIV-uninfected girls (21.5% vs. 4.8%, respectively). In multivariate analysis, use of hormonal (either estrogen/progesterone oral combination or medroxyprogesterone acetate intramuscular) contraceptives, high cervical mucous concentrations of interleukin (IL)-12, a positive HPV test, and persistent low-grade squamous intraepithelial lesion (LSIL) were significantly associated with the development of HSIL.
CONCLUSIONS: The incidence of HSIL was alarmingly high in HIV-infected adolescent girls. However, when other predictors were considered in multivariate analysis, HIV status was not retained in the model. The heightened risk for HSIL associated with persistent LSIL underscores the need to closely monitor HIV-infected adolescents with LSIL. The risk for HSIL associated with high concentrations of IL-12 may be suggestive of a local immune dysregulation. The role of hormonal contraception as a risk factor deserves further investigation. Copyright 2004 Infectious Diseases Society of America

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378433     DOI: 10.1086/424466

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin.

Authors:  Michelle R Iannacone; Wei Wang; Heather G Stockwell; Kathleen O'Rourke; Anna R Giuliano; Vernon K Sondak; Jane L Messina; Richard G Roetzheim; Basil S Cherpelis; Neil A Fenske; Kristina M Michael; Tim Waterboer; Michael Pawlita; Dana E Rollison
Journal:  J Infect Dis       Date:  2012-06-01       Impact factor: 5.226

2.  Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya.

Authors:  Hillary Mabeya; Kareem Khozaim; Tao Liu; Omenge Orango; David Chumba; Latha Pisharodi; Jane Carter; Susan Cu-Uvin
Journal:  J Low Genit Tract Dis       Date:  2012-04       Impact factor: 1.925

3.  Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.

Authors:  Ligia A Pinto; Timothy J Wilkin; Troy J Kemp; Martha Abrahamsen; Kimberly Isaacs-Soriano; Yuanji Pan; Jennifer Webster-Cyriaque; Joel M Palefsky; Anna R Giuliano
Journal:  Vaccine       Date:  2019-03-30       Impact factor: 3.641

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

5.  Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

Authors:  Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

6.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

7.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

8.  High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study.

Authors:  Deepa Reddy; Joseph Njala; Penny Stocker; Alan Schooley; Martiniano Flores; Chi-Hong Tseng; Colin Pfaff; Perry Jansen; Ronald T Mitsuyasu; Risa M Hoffman
Journal:  Int J STD AIDS       Date:  2014-06-13       Impact factor: 1.359

9.  High-grade cervical disease in adolescents with HIV.

Authors:  L Stewart Massad; Charlesnika T Evans; Gypsyamber D'Souza; Teresa Darragh; Howard Minkoff; Donna Henry; Lakshmi Goparaju; Laila I Muderspach; D Heather Watts
Journal:  J Low Genit Tract Dis       Date:  2008-07       Impact factor: 1.925

Review 10.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.